Please assess the completion status of the following clinical trial:

Trial Title: Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Severe persistent asthma with the following characteristics:~* Uncontrolled according to Global Initiative for Asthma (GINA) 2007 guidelines and at least 2 exacerbations having required systemic corticosteroid and/or at least 1 hospitalization or emergency room visit in the past year.~* Treated with high-dose inhaled corticosteroid (i.e. \> 1,000 µg beclometasone dipropionate equivalent per day) plus inhaled long-acting β2 agonist (with or without maintenance oral corticosteroid).~* Non-atopic, i.e. negative blood multiallergic testing and negative Aspergillus-specific IgE-radio allergosorbent blood test and negative skin prick tests to a battery of common aeroallergens~Exclusion Criteria:~* Current smokers or smoking history stopped for less than 3 years or \> 10 pack years.~* Asthma exacerbation during the 4 weeks prior to randomization.~* Active lung disease other than non-atopic asthma.~* Patients with an active cancer, a suspicion of cancer or any history of cancer with less than 5 disease free years.~* Pregnant or nursing (lactating) women.~* Treatment with omalizumab.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: EXPERIMENTAL): Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).